Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PF-06815345 in Healthy Adults
NCT02654899Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06815345 in hypercholesterolemia (5 arms), sponsored by Pfizer. Primary endpoint: Number of Subjects With Treatment Emergent Treatment-Related Adverse Events. Started Nov 2015; status: terminated.
02
Drugs
PF-06815345
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02654899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654899.